Medically reviewed by clinical staff at OC Weight Loss and Medspa. Last updated May 2026.
Bottom line: To qualify for Mounjaro on its FDA-approved label, you need a diagnosis of type 2 diabetes. To qualify for the same active ingredient (tirzepatide) for weight loss, your prescriber will use Zepbound — which requires a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity such as hypertension, dyslipidemia, sleep apnea, or fatty liver disease. Baseline labs and a screen for contraindications (notably medullary thyroid carcinoma history and pancreatitis) are required. Insurance prior authorization is a separate hurdle from clinical qualification.
“How do I qualify for Mounjaro?” is one of the most common questions we hear in a first GLP-1 consultation. It is also one of the most misunderstood, because there are really two questions inside it: do I medically qualify, and will insurance pay for it? This guide walks through both. For a wider review of the medication class, see our GLP-1 weight loss guide; for the specific clinical write-up on the active ingredient, see tirzepatide for weight loss.
What is the difference between Mounjaro and Zepbound?
The active ingredient is identical: tirzepatide. The pen device is the same, the dose strengths are the same, the manufacturer is the same. The difference is the FDA-approved label.
- Mounjaro is FDA-approved for the treatment of type 2 diabetes.
- Zepbound is FDA-approved for chronic weight management in adults with obesity, and in 2025 also for moderate-to-severe obstructive sleep apnea in adults with obesity.
If a patient has type 2 diabetes and obesity, they may qualify for either name on label. If a patient does not have diabetes and wants tirzepatide for weight loss, the appropriate prescription on label is Zepbound. Off-label Mounjaro for weight loss in non-diabetic patients still happens, but it is not the path we recommend because it complicates insurance and audit risk for the prescriber.
Who qualifies for Mounjaro?
The FDA label for Mounjaro is type 2 diabetes in adults. Qualifying clinically requires:
- A diagnosis of type 2 diabetes (confirmed by HbA1c, fasting glucose, or oral glucose tolerance test)
- An adult patient (18 years or older)
- No contraindications (see below)
Most insurance plans use these same criteria, sometimes with additional requirements such as a documented trial of metformin first or a minimum HbA1c threshold.
Who qualifies for tirzepatide for weight loss (Zepbound)?
If you do not have type 2 diabetes, the FDA-approved path to tirzepatide is Zepbound, with these criteria:
- A BMI of 30 or higher (obesity), OR
- A BMI of 27 or higher (overweight) with at least one weight-related comorbidity
“Weight-related comorbidity” covers a defined list including:
- Hypertension
- Dyslipidemia (high cholesterol or triglycerides)
- Type 2 diabetes or prediabetes
- Obstructive sleep apnea
- Non-alcoholic fatty liver disease (NAFLD) or MASH
- Cardiovascular disease
- Polycystic ovary syndrome (PCOS)
- Osteoarthritis
BMI is calculated as weight in kilograms divided by height in meters squared. Online calculators are accurate as long as you enter measured height and weight, not estimates. Body composition matters in edge cases — a very muscular patient may have a high BMI without true obesity — but for nearly everyone, BMI is the metric your prescriber and your insurance will use.
What labs does Mounjaro require?
Most clinics, including ours, run a baseline panel before starting tirzepatide. The exact panel varies by clinician, but the standard core includes:
- HbA1c and fasting glucose — required to confirm diabetes status and to track changes
- Comprehensive metabolic panel — kidney and liver function
- Lipid panel — total cholesterol, LDL, HDL, triglycerides
- TSH (thyroid) — to rule out untreated thyroid disease that affects weight
- Vitamin D and vitamin B12 — common deficiencies that are worth correcting before starting
- Lipase (some clinics) — baseline before a drug with a pancreatitis warning
For women of reproductive age, a pregnancy test is required before starting. Tirzepatide is contraindicated in pregnancy. Hormonal birth-control effectiveness can be reduced during dose escalation for the first four weeks, so a backup method is recommended.
Who cannot take Mounjaro?
The hard contraindications from the FDA label are:
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple endocrine neoplasia syndrome type 2 (MEN-2)
- Known serious hypersensitivity to tirzepatide or any excipient
- Pregnancy
Strong relative contraindications — where the prescriber needs a careful conversation before starting:
- History of pancreatitis. Tirzepatide carries a pancreatitis warning. A single prior episode is not necessarily a hard stop, but it raises the threshold.
- Severe gastroparesis or other severe GI motility disorders. Slowed gastric emptying is part of how the drug works; in patients who already have slow emptying, this can cause significant symptoms.
- Active gallbladder disease. GLP-1 medications are associated with gallstone formation, especially during rapid weight loss.
- Significant kidney impairment. The drug is not contraindicated but dehydration from GI side effects can precipitate acute kidney injury, so closer monitoring is warranted.
- Diabetic retinopathy. Rapid improvements in blood sugar can transiently worsen retinopathy; an ophthalmology check is reasonable.
Breastfeeding is a gray zone. There are no human safety data; many clinicians will wait until weaning. This decision belongs to the patient and their clinician.
How does Mounjaro insurance prior authorization work?
Insurance prior authorization is a separate process from clinical qualification. Even if you medically qualify on label, the insurance plan can require additional documentation before paying.
Typical prior-auth requirements for Mounjaro (diabetes label):
- Confirmed type 2 diabetes diagnosis with HbA1c or fasting glucose values
- Documented trial of metformin (or a documented intolerance or contraindication)
- Sometimes a minimum HbA1c threshold
- Treatment plan signed by the prescriber
Typical prior-auth requirements for Zepbound (weight loss label) — where covered:
- Documented BMI meeting the threshold
- Documented weight-related comorbidity if BMI is 27–29.9
- Documented prior weight-loss attempt — often a structured lifestyle program of three to six months
- Sometimes a re-authorization at six months requiring 5% weight loss to continue coverage
The prior-auth landscape changes quarterly. The best way to know what your plan covers is to ask the pharmacy to run a test claim with your prescription — formulary websites are often months out of date.
What does Mounjaro cost without insurance?
Cash price at the pharmacy (May 2026, U.S.):
- Mounjaro: approximately $1,050 per month for any dose
- Zepbound: approximately $1,060 per month at the pharmacy; Lilly Direct offers vial-form Zepbound at a reduced cash price (~$349–$549/month for the lower doses) for patients paying cash
Compounded tirzepatide from a state-licensed compounding pharmacy is commonly priced between $250 and $500 per month. Compounded GLP-1 supply is governed by FDA shortage status and has shifted multiple times in 2024 and 2025. Our post on compounded tirzepatide vs brand covers the current rules and trade-offs.
What happens at the first appointment?
A typical first visit for a GLP-1 program covers:
- Full medical history. Personal and family history (especially thyroid cancer history), prior pancreatitis, GI motility issues, medications, prior weight-loss attempts.
- Vitals and BMI. Measured height and weight, blood pressure, waist circumference.
- Baseline labs. Ordered if not already done within the last 6 to 12 months.
- Discussion of expectations and timeline. What 5%, 10%, and 15% weight loss looks like on your body; what to expect during dose titration; the role of protein, resistance training, and sleep.
- Insurance check. Whether your plan covers Mounjaro or Zepbound, what the prior-auth criteria are, what cash-pay options exist.
- Prescription and injection training. Once labs are reviewed, a starter dose is prescribed, and the team walks through pen technique.
Most programs schedule a follow-up at the first dose increase, then every 4 to 8 weeks during titration. For more on our broader medical weight loss approach, see our medical weight loss injections guide.
Frequently asked questions
Can I get Mounjaro if I am not diabetic?
Mounjaro itself is FDA-approved for type 2 diabetes. The same active ingredient (tirzepatide) is FDA-approved for chronic weight management under the name Zepbound. For non-diabetic patients seeking tirzepatide for weight loss, Zepbound is the on-label choice.
Will insurance cover Mounjaro for weight loss?
Usually no, because Mounjaro is not FDA-labeled for weight loss. For weight loss coverage, the prescription should be Zepbound. Some employer plans cover Zepbound; many exclude weight-loss medications entirely. Medicare does not currently cover obesity medications outside the cardiovascular indication for semaglutide.
What BMI do I need to qualify for tirzepatide?
For Zepbound: a BMI of 30 or higher, or 27 or higher with a documented weight-related comorbidity such as hypertension, dyslipidemia, or sleep apnea. For Mounjaro: BMI is not a label criterion, but a type 2 diabetes diagnosis is required.
Do I need to try other medications first?
Some insurance plans require a documented trial of metformin (for the diabetes indication) or a structured lifestyle program (for the weight-loss indication) before approving tirzepatide. The FDA label itself does not require step-therapy.
Can I qualify with a thyroid nodule?
A benign thyroid nodule is generally not a contraindication. A personal or family history of medullary thyroid carcinoma (MTC) is an absolute contraindication. If you have a known nodule, sharing prior thyroid biopsy results and family history with your prescriber is important.
How long after labs can I start?
Once baseline labs are reviewed and there are no contraindications, a starter dose can typically be prescribed at the next visit. If the medication is being run through insurance and requires prior authorization, expect 5 to 15 business days for approval; cash-pay starts faster.
Can I get tirzepatide if my BMI is 26?
Not on the FDA label. The label cutoff for Zepbound is BMI 27 with a comorbidity, or BMI 30. Off-label use below those thresholds is possible but is rarely covered by insurance and warrants a careful clinical discussion about risk versus benefit at a lower BMI.
Talk to a clinician at OC Weight Loss and Medspa
Qualifying for Mounjaro on paper and getting it covered, dispensed, and titrated correctly are different problems. Our GLP-1 weight loss program handles the lab work, the insurance navigation, and the dose adjustments under one roof.
Book a free consultation
Book a Free Consultation